Maternal serum CA 19-9 and CA 15-3 levels in pregnancies affected by trisomy 21
ABSTRACT Objectives To investigate the levels of tumour markers CA 19–9 and CA 15–3 in the first trimester maternal serum of euploid control and trisomy 21 pregnancies. Methods Maternal serum marker levels of 69 trisomy 21 and 388 euploid controls were quantified by the Kryptor analyser, and levels...
Gespeichert in:
| Veröffentlicht in: | Prenatal diagnosis 2012-07, Vol.32 (7), p.644-648 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 648 |
|---|---|
| container_issue | 7 |
| container_start_page | 644 |
| container_title | Prenatal diagnosis |
| container_volume | 32 |
| creator | Akinlade, F. Cowans, N. J. Kisanga, M. C. Spencer, K. |
| description | ABSTRACT
Objectives
To investigate the levels of tumour markers CA 19–9 and CA 15–3 in the first trimester maternal serum of euploid control and trisomy 21 pregnancies.
Methods
Maternal serum marker levels of 69 trisomy 21 and 388 euploid controls were quantified by the Kryptor analyser, and levels were compared between the two groups after analysis for confounding factors. Monte Carlo simulation was carried out to determine the effect of adding potential markers to the combined test.
Results
Neither marker was affected by gestational age; however, CA 19–9 required correction for maternal weight. CA 19–9 was significantly increased in trisomy 21 pregnancies (0.98 MoM in euploid, 1.16 MoM in trisomy 21, p = 0.024). Levels of CA 15–3 were not found to differ significantly (1.03 MoM in euploid, 1.09 in trisomy 21, p = 0.130). Detection rates were unaffected by addition of CA 19–9 to the combined test.
Conclusion
Although a small significant increase in CA 19–9 levels was found in trisomy 21 group, it is unlikely to be of any use as part of a trisomy 21 screening tool. © 2012 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/pd.3875 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1023294225</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1023294225</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3555-a4a26e5b8a2e011cbf85c32698ef69d9b900dd534b5e06be1fc73cb5b3d8f8ee3</originalsourceid><addsrcrecordid>eNp10MlOwzAUhWELgWgZxBsg70BCKR7qxF5CmVUGMQiJjeXhBgWSNNgp0Lcn0MKO1b2LT__iILRFyYASwvYbP-AyE0uoT4nKEsIYX0Z9QrufS0F7aC3Glw5KprJV1GMsE0zxrI-uL00LoTYljhCmFR4dYKoShU3tf36RcFzCO5QRFzVuAjzXpnYFRGzyHFwLHtsZbkMRJ9UMM7qBVnJTRthc3HX0cHJ8PzpLxten56ODceK4ECIxQ8NSEFYaBoRSZ3MpHGepkpCnyiurCPFe8KEVQFILNHcZd1ZY7mUuAfg62p13mzB5m0JsdVVEB2VpaphMo6aEcaaGjImO7sypC5MYA-S6CUVlwqxD-ns93Xj9vV4ntxfRqa3A_7nfuTqwNwcfRQmz_zr65miRS-a6iC18_mkTXnWa8c49Xp3qx6eLQ3YnL_Qt_wL0dYQS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1023294225</pqid></control><display><type>article</type><title>Maternal serum CA 19-9 and CA 15-3 levels in pregnancies affected by trisomy 21</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Akinlade, F. ; Cowans, N. J. ; Kisanga, M. C. ; Spencer, K.</creator><creatorcontrib>Akinlade, F. ; Cowans, N. J. ; Kisanga, M. C. ; Spencer, K.</creatorcontrib><description>ABSTRACT
Objectives
To investigate the levels of tumour markers CA 19–9 and CA 15–3 in the first trimester maternal serum of euploid control and trisomy 21 pregnancies.
Methods
Maternal serum marker levels of 69 trisomy 21 and 388 euploid controls were quantified by the Kryptor analyser, and levels were compared between the two groups after analysis for confounding factors. Monte Carlo simulation was carried out to determine the effect of adding potential markers to the combined test.
Results
Neither marker was affected by gestational age; however, CA 19–9 required correction for maternal weight. CA 19–9 was significantly increased in trisomy 21 pregnancies (0.98 MoM in euploid, 1.16 MoM in trisomy 21, p = 0.024). Levels of CA 15–3 were not found to differ significantly (1.03 MoM in euploid, 1.09 in trisomy 21, p = 0.130). Detection rates were unaffected by addition of CA 19–9 to the combined test.
Conclusion
Although a small significant increase in CA 19–9 levels was found in trisomy 21 group, it is unlikely to be of any use as part of a trisomy 21 screening tool. © 2012 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0197-3851</identifier><identifier>EISSN: 1097-0223</identifier><identifier>DOI: 10.1002/pd.3875</identifier><identifier>PMID: 22752937</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adult ; Biomarkers ; Body Weight ; CA-19-9 Antigen - blood ; Case-Control Studies ; Chorionic Gonadotropin, beta Subunit, Human - blood ; Down Syndrome - blood ; Down Syndrome - diagnosis ; Female ; Gestational Age ; Humans ; Mucin-1 - blood ; Pregnancy ; Pregnancy Trimester, First - blood ; Pregnancy-Associated Plasma Protein-A - analysis ; Prenatal Diagnosis - methods ; Retrospective Studies</subject><ispartof>Prenatal diagnosis, 2012-07, Vol.32 (7), p.644-648</ispartof><rights>2012 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3555-a4a26e5b8a2e011cbf85c32698ef69d9b900dd534b5e06be1fc73cb5b3d8f8ee3</citedby><cites>FETCH-LOGICAL-c3555-a4a26e5b8a2e011cbf85c32698ef69d9b900dd534b5e06be1fc73cb5b3d8f8ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpd.3875$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpd.3875$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22752937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akinlade, F.</creatorcontrib><creatorcontrib>Cowans, N. J.</creatorcontrib><creatorcontrib>Kisanga, M. C.</creatorcontrib><creatorcontrib>Spencer, K.</creatorcontrib><title>Maternal serum CA 19-9 and CA 15-3 levels in pregnancies affected by trisomy 21</title><title>Prenatal diagnosis</title><addtitle>Prenat Diagn</addtitle><description>ABSTRACT
Objectives
To investigate the levels of tumour markers CA 19–9 and CA 15–3 in the first trimester maternal serum of euploid control and trisomy 21 pregnancies.
Methods
Maternal serum marker levels of 69 trisomy 21 and 388 euploid controls were quantified by the Kryptor analyser, and levels were compared between the two groups after analysis for confounding factors. Monte Carlo simulation was carried out to determine the effect of adding potential markers to the combined test.
Results
Neither marker was affected by gestational age; however, CA 19–9 required correction for maternal weight. CA 19–9 was significantly increased in trisomy 21 pregnancies (0.98 MoM in euploid, 1.16 MoM in trisomy 21, p = 0.024). Levels of CA 15–3 were not found to differ significantly (1.03 MoM in euploid, 1.09 in trisomy 21, p = 0.130). Detection rates were unaffected by addition of CA 19–9 to the combined test.
Conclusion
Although a small significant increase in CA 19–9 levels was found in trisomy 21 group, it is unlikely to be of any use as part of a trisomy 21 screening tool. © 2012 John Wiley & Sons, Ltd.</description><subject>Adult</subject><subject>Biomarkers</subject><subject>Body Weight</subject><subject>CA-19-9 Antigen - blood</subject><subject>Case-Control Studies</subject><subject>Chorionic Gonadotropin, beta Subunit, Human - blood</subject><subject>Down Syndrome - blood</subject><subject>Down Syndrome - diagnosis</subject><subject>Female</subject><subject>Gestational Age</subject><subject>Humans</subject><subject>Mucin-1 - blood</subject><subject>Pregnancy</subject><subject>Pregnancy Trimester, First - blood</subject><subject>Pregnancy-Associated Plasma Protein-A - analysis</subject><subject>Prenatal Diagnosis - methods</subject><subject>Retrospective Studies</subject><issn>0197-3851</issn><issn>1097-0223</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MlOwzAUhWELgWgZxBsg70BCKR7qxF5CmVUGMQiJjeXhBgWSNNgp0Lcn0MKO1b2LT__iILRFyYASwvYbP-AyE0uoT4nKEsIYX0Z9QrufS0F7aC3Glw5KprJV1GMsE0zxrI-uL00LoTYljhCmFR4dYKoShU3tf36RcFzCO5QRFzVuAjzXpnYFRGzyHFwLHtsZbkMRJ9UMM7qBVnJTRthc3HX0cHJ8PzpLxten56ODceK4ECIxQ8NSEFYaBoRSZ3MpHGepkpCnyiurCPFe8KEVQFILNHcZd1ZY7mUuAfg62p13mzB5m0JsdVVEB2VpaphMo6aEcaaGjImO7sypC5MYA-S6CUVlwqxD-ns93Xj9vV4ntxfRqa3A_7nfuTqwNwcfRQmz_zr65miRS-a6iC18_mkTXnWa8c49Xp3qx6eLQ3YnL_Qt_wL0dYQS</recordid><startdate>201207</startdate><enddate>201207</enddate><creator>Akinlade, F.</creator><creator>Cowans, N. J.</creator><creator>Kisanga, M. C.</creator><creator>Spencer, K.</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201207</creationdate><title>Maternal serum CA 19-9 and CA 15-3 levels in pregnancies affected by trisomy 21</title><author>Akinlade, F. ; Cowans, N. J. ; Kisanga, M. C. ; Spencer, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3555-a4a26e5b8a2e011cbf85c32698ef69d9b900dd534b5e06be1fc73cb5b3d8f8ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Biomarkers</topic><topic>Body Weight</topic><topic>CA-19-9 Antigen - blood</topic><topic>Case-Control Studies</topic><topic>Chorionic Gonadotropin, beta Subunit, Human - blood</topic><topic>Down Syndrome - blood</topic><topic>Down Syndrome - diagnosis</topic><topic>Female</topic><topic>Gestational Age</topic><topic>Humans</topic><topic>Mucin-1 - blood</topic><topic>Pregnancy</topic><topic>Pregnancy Trimester, First - blood</topic><topic>Pregnancy-Associated Plasma Protein-A - analysis</topic><topic>Prenatal Diagnosis - methods</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akinlade, F.</creatorcontrib><creatorcontrib>Cowans, N. J.</creatorcontrib><creatorcontrib>Kisanga, M. C.</creatorcontrib><creatorcontrib>Spencer, K.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Prenatal diagnosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akinlade, F.</au><au>Cowans, N. J.</au><au>Kisanga, M. C.</au><au>Spencer, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maternal serum CA 19-9 and CA 15-3 levels in pregnancies affected by trisomy 21</atitle><jtitle>Prenatal diagnosis</jtitle><addtitle>Prenat Diagn</addtitle><date>2012-07</date><risdate>2012</risdate><volume>32</volume><issue>7</issue><spage>644</spage><epage>648</epage><pages>644-648</pages><issn>0197-3851</issn><eissn>1097-0223</eissn><abstract>ABSTRACT
Objectives
To investigate the levels of tumour markers CA 19–9 and CA 15–3 in the first trimester maternal serum of euploid control and trisomy 21 pregnancies.
Methods
Maternal serum marker levels of 69 trisomy 21 and 388 euploid controls were quantified by the Kryptor analyser, and levels were compared between the two groups after analysis for confounding factors. Monte Carlo simulation was carried out to determine the effect of adding potential markers to the combined test.
Results
Neither marker was affected by gestational age; however, CA 19–9 required correction for maternal weight. CA 19–9 was significantly increased in trisomy 21 pregnancies (0.98 MoM in euploid, 1.16 MoM in trisomy 21, p = 0.024). Levels of CA 15–3 were not found to differ significantly (1.03 MoM in euploid, 1.09 in trisomy 21, p = 0.130). Detection rates were unaffected by addition of CA 19–9 to the combined test.
Conclusion
Although a small significant increase in CA 19–9 levels was found in trisomy 21 group, it is unlikely to be of any use as part of a trisomy 21 screening tool. © 2012 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>22752937</pmid><doi>10.1002/pd.3875</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0197-3851 |
| ispartof | Prenatal diagnosis, 2012-07, Vol.32 (7), p.644-648 |
| issn | 0197-3851 1097-0223 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1023294225 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Biomarkers Body Weight CA-19-9 Antigen - blood Case-Control Studies Chorionic Gonadotropin, beta Subunit, Human - blood Down Syndrome - blood Down Syndrome - diagnosis Female Gestational Age Humans Mucin-1 - blood Pregnancy Pregnancy Trimester, First - blood Pregnancy-Associated Plasma Protein-A - analysis Prenatal Diagnosis - methods Retrospective Studies |
| title | Maternal serum CA 19-9 and CA 15-3 levels in pregnancies affected by trisomy 21 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T12%3A04%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maternal%20serum%20CA%2019-9%20and%20CA%2015-3%20levels%20in%20pregnancies%20affected%20by%20trisomy%2021&rft.jtitle=Prenatal%20diagnosis&rft.au=Akinlade,%20F.&rft.date=2012-07&rft.volume=32&rft.issue=7&rft.spage=644&rft.epage=648&rft.pages=644-648&rft.issn=0197-3851&rft.eissn=1097-0223&rft_id=info:doi/10.1002/pd.3875&rft_dat=%3Cproquest_cross%3E1023294225%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1023294225&rft_id=info:pmid/22752937&rfr_iscdi=true |